Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145

Inclusion Criteria: * Healthy men or women of non-childbearing potential between 18-50 years of age * Body Mass Index (BMI): 18.0 - 32.0 kg/m2 * In good health, determined by no clinically significant findings from clinical evaluations * Provided written informed consent prior to any study specific procedures Exclusion Criteria: * Women of childbearing potential * Evidence of clinically significant medical conditions * History of gastrointestinal disease or surgery that may affect drug absorption * Positive or indeterminate Tuberculosis -spot test at screening * Any active infection at the time of screening or admission * Consumption of any nutrients known to modulate cytochrome P450 enzyme activity within 14 days prior to administration of study drug, during the study, and until after discharge